A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
1 other identifier
interventional
530
25 countries
179
Brief Summary
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Feb 2025
Longer than P75 for phase_3
179 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 16, 2024
CompletedFirst Posted
Study publicly available on registry
October 17, 2024
CompletedStudy Start
First participant enrolled
February 25, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 6, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 5, 2031
July 20, 2026
July 1, 2026
3.1 years
October 16, 2024
July 17, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Overall Survival (OS)
Up to 5 years
Secondary Outcomes (7)
Time to definitive deterioration (TTDD)based on the LCSS ASBI defined as the time from randomization until a definitive clinically meaningful decline (≥ 10 point increase from baseline in LCSS ASBI score).
Up to 5 years
Number of participants with Adverse Events (AEs)
Up to 135 days after last treatment
Number of Participants with Serious Adverse Events (SAEs)
Up to 135 days after last treatment
Number of Participants with Adverse Events (AEs) leading to discontinuation and death
Up to 135 days after last treatment
Objective Response (OR)
Up to 5 years
- +2 more secondary outcomes
Study Arms (2)
Arm A
EXPERIMENTALArm B
ACTIVE COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
- Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale.
- Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system
You may not qualify if:
- Participants have already received certain types of treatment for extensive stage small cell lung cancer
- Participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (183)
Southern Cancer Center, PC
Daphne, Alabama, 36526, United States
Local Institution - 0283
Hot Springs, Arkansas, 71913, United States
Florida Cancer Specialists - South
Fort Myers, Florida, 33901, United States
Mid Florida Hematology and Oncology Center
Orange City, Florida, 32763, United States
Florida Cancer Specialists - North
St. Petersburg, Florida, 33705, United States
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
Marietta, Georgia, 30060, United States
Illinois Cancer Care
Peoria, Illinois, 61615, United States
Local Institution - 0037
Minneapolis, Minnesota, 55407, United States
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico, 87106, United States
Duke Cancer Institute
Durham, North Carolina, 27710, United States
Sanford Medical Center
Bismarck, North Dakota, 58501, United States
Sanford Fargo Medical Center
Fargo, North Dakota, 58102, United States
Oncology Hematology Care
Cincinnati, Ohio, 45242, United States
Sanford Cancer Center
Sioux Falls, South Dakota, 57104, United States
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
Texas Oncology - Central/South Texas
Austin, Texas, 78705, United States
Texas Oncology - Northeast Texas
Tyler, Texas, 75702, United States
Oncology & Hematology Associates of Southwest Virginia, Inc.
Roanoke, Virginia, 24014, United States
Swedish Cancer Institute - Edmonds
Edmonds, Washington, 98026, United States
Swedish Medical Center
Seattle, Washington, 98104, United States
Local Institution - 0079
Ciudad Autónoma de Buenos Aires, Buenos Aires, C1426ANZ, Argentina
Local Institution - 0077
ABB, Buenos Aires F.D., C1199ABB, Argentina
Local Institution - 0100
Buenos Aires, Buenos Aires F.D., C1417DTB, Argentina
Local Institution - 0080
CABA, Buenos Aires F.D., C1430EGF, Argentina
Local Institution - 0094
Río Cuarto, Córdoba Province, X5800AEV, Argentina
Local Institution - 0202
Campbelltown, New South Wales, 2560, Australia
Local Institution - 0106
Penrith, New South Wales, 2750, Australia
Local Institution - 0105
Brisbane, Queensland, 4120, Australia
Local Institution - 0190
Ballarat Central, Victoria, 3350, Australia
Local Institution - 0175
Murdoch, Western Australia, 6150, Australia
Local Institution - 0253
Graz, Styria, 8036, Austria
Local Institution - 0251
Wels, Upper Austria, 4600, Austria
Local Institution - 0252
Linz, 4021, Austria
Local Institution - 0255
Rankweil, 6830, Austria
Local Institution - 0198
Brussels, Bruxelles-Capitale, Région de, 1200, Belgium
Local Institution - 0091
Ghent, Oost-Vlaanderen, 9000, Belgium
Local Institution - 0187
Sint-Niklaas, Oost-Vlaanderen, B-9100, Belgium
Local Institution - 0092
Liège, 4000, Belgium
Local Institution - 0166
Fortaleza, Ceará, 60135-237, Brazil
Local Institution - 0165
Porto Alegre, Rio Grande do Sul, 90035-903, Brazil
Local Institution - 0169
Porto Alegre, Rio Grande do Sul, 90610-000, Brazil
Local Institution - 0170
Santa Cruz do Sul, Rio Grande do Sul, 96830-180, Brazil
Local Institution - 0163
Itajaí, Santa Catarina, 88301-220, Brazil
Local Institution - 0178
Barretos, São Paulo, 14784400, Brazil
Local Institution - 0111
São Paulo, São Paulo, 01509-010, Brazil
Local Institution - 0289
Edmonton, Alberta, T6G 1Z2, Canada
Local Institution - 0290
Chicoutimi, Quebec, G7H 5H6, Canada
Local Institution - 0288
Québec, Quebec, G1V 4G5, Canada
Local Institution - 0287
Rimouski, Quebec, G5L 5T1, Canada
Local Institution - 0086
Santiago, Santiago Metropolitan, 0, Chile
Local Institution - 0085
Santiago, Santiago Metropolitan, 7500921, Chile
Local Institution - 0083
Santiago, Santiago Metropolitan, 8330032, Chile
Local Institution - 0084
Santiago, Santiago Metropolitan, 8420383, Chile
Local Institution - 0082
Viña del Mar, Valparaiso, 2520598, Chile
Local Institution - 0204
Beijing, Beijing Municipality, 100142, China
Local Institution - 0336
Beijing, Beijing Municipality, 101149, China
Local Institution - 0203
Chongqing, Chongqing Municipality, 400030, China
Local Institution - 0308
Fuzhou, Fujian, 350014, China
Local Institution - 0212
Xiamen, Fujian, 361003, China
Local Institution - 0234
Shantou, Guangdong, 515000, China
Local Institution - 0227
Harbin, Heilongjiang, 150081, China
Local Institution - 0209
Wuhan, Hubei, 430079, China
Local Institution - 0208
Wuhan, Hubei, 430100, China
Local Institution - 0216
Changsha, Hunan, 410013, China
Local Institution - 0233
Nanchang, Jiangxi, 330006, China
Local Institution - 0244
Changchun, Jilin, 132000, China
Local Institution - 0235
Shenyang, Liaoning, 110042, China
Local Institution - 0335
Xi'an, Shaanxi, 710126, China
Local Institution - 0200
Jinan, Shandong, 250117, China
Local Institution - 0206
Shanghai, Shanghai Municipality, 200030, China
Local Institution - 0210
Shanghai, Shanghai Municipality, 200032, China
Local Institution - 0186
Shanghai, Shanghai Municipality, 200120, China
Local Institution - 0330
Chengdu, Sichuan, 610041, China
Local Institution - 0213
Tianjin, Tianjin Municipality, 300060, China
Local Institution - 0236
Hangzhou, Zhejiang, 310016, China
Local Institution - 0237
Hangzhou, Zhejiang, 310022, China
Local Institution - 0229
Linhai, Zhejiang, 317000, China
Local Institution - 0114
Brno, Brno-město, 656 53, Czechia
Local Institution - 0117
Ostrava, Ostrava Město, 703 00, Czechia
Local Institution - 0113
Prague, Praha 4, 14059, Czechia
Local Institution - 0116
Olomouc, 779 00, Czechia
Local Institution - 0048
Montpellier, Hérault, 34090, France
Local Institution - 0040
La Tronche, Isère, 38700, France
Local Institution - 0052
Lille, Nord, 59037, France
Local Institution - 0044
Gleizé, Rhône, 69400, France
Local Institution - 0051
Pierre-Bénite, Rhône, 69310, France
Local Institution - 0047
Créteil, Val-de-Marne, 94010, France
Local Institution - 0038
Villejuif, Val-de-Marne, 94800, France
Local Institution - 0043
Marseille, 13915, France
Local Institution - 0050
Paris, 75248, France
Local Institution - 0215
Quimper, 29000, France
Local Institution - 0256
Frankfurt am Main, Hesse, 60488, Germany
Local Institution - 0262
Oldenburg, Lower Saxony, 26121, Germany
Local Institution - 0261
Cologne, North Rhine-Westphalia, 51109, Germany
Local Institution - 0265
Halle, Saxony-Anhalt, 06120, Germany
Local Institution - 0257
Bad Berka, Thuringia, 99437, Germany
Local Institution - 0258
Gauting, 82131, Germany
Local Institution - 0259
Großhansdorf, 22927, Germany
Thoraxklinik-Heidelberg gGmbH
Heidelberg, 69126, Germany
Local Institution - 0264
Stuttgart, 70736, Germany
Local Institution - 0063
Athens, Attikí, 115 26, Greece
Local Institution - 0064
Athens, Attikí, 115 27, Greece
Local Institution - 0062
Thessaloniki, Kentrikí Makedonía, 540 07, Greece
Local Institution - 0058
Thessaloniki, Thessaloníki, 570 01, Greece
Local Institution - 0059
Larissa, Thessalía, 41110, Greece
Local Institution - 0274
Bengaluru, Karnataka, 560017, India
Local Institution - 0278
New Delhi, National Capital Territory of Delhi, 110029, India
Local Institution - 0271
Madurai, Tamil Nadu, 625107, India
Local Institution - 0277
Varanasi, Uttar Pradesh, 221005, India
Local Institution - 0273
Kolkata, West Bengal, 700094, India
Local Institution - 0072
Naples, Campania, 80131, Italy
Local Institution - 0068
Milan, Lombardy, 20133, Italy
Local Institution - 0069
Rome, Roma, 00144, Italy
Local Institution - 0110
Perugia, Umbria, 06132, Italy
Local Institution - 0070
Peschiera del Garda, Verona, 37019, Italy
Local Institution - 0074
Bologna, 40138, Italy
Local Institution - 0067
Milan, 20141, Italy
Local Institution - 0319
Matsuyama, Ehime, 791-0280, Japan
Local Institution - 0292
Kurume, Fukuoka, 830-0011, Japan
Local Institution - 0313
Sapporo, Hokkaido, 0608648, Japan
Local Institution - 0323
Kobe, Hyōgo, 650-0047, Japan
Local Institution - 0321
Kanazawa, Ishikawa-ken, 920-8641, Japan
Local Institution - 0316
Yokohama, Kanagawa, 236-0051, Japan
Local Institution - 0291
Sendai, Miyagi, 9810914, Japan
Local Institution - 0324
Kashihara, Nara, 634-8522, Japan
Local Institution - 0328
Kurashiki, Okayama-ken, 710-8602, Japan
Local Institution - 0317
Hirakata, Osaka, 573-1191, Japan
Local Institution - 0314
Ōsaka-sayama, Osaka, 589-8511, Japan
Local Institution - 0325
Takatsuki, Osaka, 569-8686, Japan
Local Institution - 0320
Hidaka, Saitama, 350-1298, Japan
Local Institution - 0318
Ina-machi, Saitama, 362-0806, Japan
Local Institution - 0322
Hamamatsu, Shizuoka, 431-3192, Japan
Local Institution - 0326
Bunkyo-ku, Tokyo, 1138603, Japan
Local Institution - 0315
Koto, Tokyo, 135-8550, Japan
Local Institution - 0327
Fukushima, 960-1295, Japan
Hospital Kuala Lumpur
Kuala Lumpur, Kuala Lumpur, 50586, Malaysia
Local Institution - 0312
Kuala Lumpur, Kuala Lumpur, 50603, Malaysia
Local Institution - 0311
Kuching, Sarawak, 93586, Malaysia
Local Institution - 0146
Guadalajara, Jalisco, 44630, Mexico
Local Institution - 0145
Puebla City, 72424, Mexico
Local Institution - 0097
Amsterdam, North Holland, 1081 HV, Netherlands
Local Institution - 0099
Arnhem, 6815 AD, Netherlands
Local Institution - 0098
Groningen, 9713 GZ, Netherlands
Local Institution - 0193
Konin, Greater Poland Voivodeship, 62-500, Poland
Local Institution - 0241
Poznan, Greater Poland Voivodeship, 60-192, Poland
Local Institution - 0192
Prabuty, Pomeranian Voivodeship, 82-550, Poland
Local Institution - 0195
Bydgoszcz, 85796, Poland
Local Institution - 0189
Lodz, Łódź Voivodeship, 93-338, Poland
Local Institution - 0133
Bucharest, Bucharest, 013812, Romania
Local Institution - 0135
Bucharest, Bucharest, 022328, Romania
Local Institution - 0137
Florești, Cluj, 407280, Romania
Local Institution - 0140
Craiova, Dolj, 200542, Romania
Local Institution - 0141
Cluj-Napoca, 400015, Romania
S.C. Centrul de Oncologie Euroclinic S.R.L.
Iași, 700106, Romania
Institutul Regional de Oncologie
Iași, 700483, Romania
Local Institution - 0305
Cheongju-si, Chungcheongbuk-do [Chungbuk], 28644, South Korea
Local Institution - 0286
Seongnam, Kyǒnggi-do, 13620, South Korea
Local Institution - 0304
Suwon, Kyǒnggi-do, 16499, South Korea
Local Institution - 0285
Seoul, Seoul-teukbyeolsi [Seoul], 03722, South Korea
Local Institution - 0293
Seoul, Seoul-teukbyeolsi [Seoul], 05505, South Korea
Local Institution - 0309
Daegu, Taegu-Kwangyǒkshi, 42601, South Korea
Local Institution - 0300
Santiago de Compostela, A Coruña [La Coruña], 15706, Spain
Local Institution - 0294
Barcelona, Catalunya [Cataluña], 08036, Spain
Local Institution - 0302
Barcelona, Catalunya [Cataluña], 08041, Spain
Local Institution - 0301
Jaén, Jaén, 23007, Spain
Local Institution - 0298
Madrid, Madrid, Comunidad de, 28034, Spain
Local Institution - 0296
Madrid, Madrid, Comunidad de, 28041, Spain
Local Institution - 0297
Majadahonda, Madrid, Comunidad de, 28222, Spain
Local Institution - 0303
Valencia, Valenciana, Comunitat, 46014, Spain
Local Institution - 0299
Seville, 41009, Spain
Local Institution - 0295
Seville, 41013, Spain
Local Institution - 0248
Chur, 7000, Switzerland
Local Institution - 0249
Winterthur, 8401, Switzerland
Local Institution - 0247
Zurich, 8091, Switzerland
Local Institution - 0158
Çiğli, İzmir, 35620, Turkey (Türkiye)
Local Institution - 0154
Adana, 01370, Turkey (Türkiye)
Local Institution - 0157
Ankara, 06010, Turkey (Türkiye)
Local Institution - 0177
Ankara, 06280, Turkey (Türkiye)
Local Institution - 0153
Istanbul, 34732, Turkey (Türkiye)
Local Institution - 0183
Central Middlesbrough, Middlesbrough, TS4 3BW, United Kingdom
Local Institution - 0159
Aberdeen, AB9 2ZB, United Kingdom
Local Institution - 0101
Manchester, M20 4BX, United Kingdom
Local Institution - 0226
Metropolitan Borough of Wirral, CH63 4JY, United Kingdom
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Bristol-Myers Squibb
Bristol-Myers Squibb
Central Study Contacts
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 16, 2024
First Posted
October 17, 2024
Study Start
February 25, 2025
Primary Completion (Estimated)
April 6, 2028
Study Completion (Estimated)
September 5, 2031
Last Updated
July 20, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR
- Time Frame
- See Plan Description
- Access Criteria
- See Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html